Abstract:Abstract Background Alzheimer’s disease (AD) mutations in amyloid precursor protein ( APP ) and presenilins ( PSENs ) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ 1–43 is more prone to aggregation and has higher toxic properties than the long-known Aβ 1–42 . However, a direct effect on Aβ 1–43 in biomaterials of individuals carrying genetic mutations in the known AD genes is yet to be determined. Methods N = 1431 AD patients ( n = 280 early-onset (EO) and n = 1151 late-onset (LO) AD) and 809 control individuals were genetically screened for APP and PSENs . For the first time, Aβ 1–43 levels were analysed in cerebrospinal fluid (CSF) of 38 individuals carrying pathogenic or unclear rare mutations or the common PSEN1 p.E318G variant and compared with Aβ 1–42 and Aβ 1–40 CSF levels. The soluble sAPPα and sAPPβ species were also measured for the first time in mutation carriers. Results A known pathogenic mutation was identified in 5.7% of EOAD patients (4.6% PSEN1 , 1.07% APP ) and in 0.3% of LOAD patients. Furthermore, 12 known variants with unclear pathogenicity and 11 novel were identified. Pathogenic and unclear mutation carriers showed a significant reduction in CSF Aβ 1–43 levels compared to controls ( p = 0.037; < 0.001). CSF Aβ 1–43 levels positively correlated with CSF Aβ 1–42 in both pathogenic and unclear carriers and controls (all p < 0.001). The p.E318G carriers showed reduced Aβ 1–43 levels ( p < 0.001), though genetic association with AD was not detected. sAPPα and sAPPβ CSF levels were significantly reduced in the group of unclear ( p = 0.006; 0.005) and p.E318G carriers ( p = 0.004; 0.039), suggesting their possible involvement in AD. Finally, using Aβ 1–43 and Aβ 1–42 levels, we could re-classify as “likely pathogenic” 3 of the unclear mutations. Conclusion This is the first time that Aβ 1–43 levels were analysed in CSF of AD patients with genetic mutations in the AD causal genes. The observed reduction of Aβ 1–43 in APP and PSENs carriers highlights the pathogenic role of longer Aβ peptides in AD pathogenesis. Alterations in Aβ 1–43 could prove useful in understanding the pathogenicity of unclear APP and PSENs variants, a critical step towards a more efficient genetic counselling.

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio in Vitro and in Vivo

Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid Β‐protein 1–42 and Its N‐Terminally Truncated Variant(s) Which Are Generated at Distinct Sites

The E280A Presenilin 1 Alzheimer Mutation Produces Increased Aβ42 Deposition and Severe Cerebellar Pathology

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations

S4-03-01: Evidence That Aberrant Post-Tgn Trafficking of Alzheimer’s APP is Sufficient to Elevate Brain A-beta 42 and May Underlie Mutant Presenilin Action

FAD-linked Mutations in Presenilin 1 Alter the Length of Abeta Peptides Derived from Betaapp Transmembrane Domain Mutants.

Mean Age-Of-Onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased A Beta 42 and Decreased A Beta 40

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production

Random Mutagenesis of Presenilin-1 Identifies Novel Mutants Exclusively Generating Long Amyloid β-Peptides

Familial Alzheimer Disease-linked Presenilin 1 Variants Enhance Production of Both Aβ1–40 and Aβ1–42 Peptides That Are Only Partially Sensitive to a Potent Aspartyl Protease Transition State Inhibitor of “Γ-Secretase”

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo.

Nonfibrillar Diffuse Amyloid Deposition Due To A Gamma(42)-Secretase Site Mutation Points To An Essential Role For N-Truncated A Beta(42) In Alzheimer'S Disease

P3-395: Mean Age-of-onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased Aβ42 and Decreased Aβ40

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

APP Substitutions V715F and L720P Alter PS1 Conformation and Differentially Affect Abeta and AICD Generation.

Advances in the β-amyloid precursor protein of Alzheimer's disease

Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes